Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment

Detalles Bibliográficos
Autores principales: Betrian, S, Ysebaert, L, Heider, K H, Delord, J P, Fournié, J J, Quillet-Mary, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148053/
https://www.ncbi.nlm.nih.gov/pubmed/27834943
http://dx.doi.org/10.1038/bcj.2016.106
_version_ 1782473789665181696
author Betrian, S
Ysebaert, L
Heider, K H
Delord, J P
Fournié, J J
Quillet-Mary, A
author_facet Betrian, S
Ysebaert, L
Heider, K H
Delord, J P
Fournié, J J
Quillet-Mary, A
author_sort Betrian, S
collection PubMed
description
format Online
Article
Text
id pubmed-5148053
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51480532016-12-23 Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment Betrian, S Ysebaert, L Heider, K H Delord, J P Fournié, J J Quillet-Mary, A Blood Cancer J Letter to the Editor Nature Publishing Group 2016-11 2016-11-11 /pmc/articles/PMC5148053/ /pubmed/27834943 http://dx.doi.org/10.1038/bcj.2016.106 Text en Copyright © 2016 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Letter to the Editor
Betrian, S
Ysebaert, L
Heider, K H
Delord, J P
Fournié, J J
Quillet-Mary, A
Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment
title Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment
title_full Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment
title_fullStr Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment
title_full_unstemmed Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment
title_short Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment
title_sort idelalisib improves cd37 antibody bi 836826 cytotoxicity against chemo-resistant /relapse-initiating cll cells: a rationale for combination treatment
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148053/
https://www.ncbi.nlm.nih.gov/pubmed/27834943
http://dx.doi.org/10.1038/bcj.2016.106
work_keys_str_mv AT betrians idelalisibimprovescd37antibodybi836826cytotoxicityagainstchemoresistantrelapseinitiatingcllcellsarationaleforcombinationtreatment
AT ysebaertl idelalisibimprovescd37antibodybi836826cytotoxicityagainstchemoresistantrelapseinitiatingcllcellsarationaleforcombinationtreatment
AT heiderkh idelalisibimprovescd37antibodybi836826cytotoxicityagainstchemoresistantrelapseinitiatingcllcellsarationaleforcombinationtreatment
AT delordjp idelalisibimprovescd37antibodybi836826cytotoxicityagainstchemoresistantrelapseinitiatingcllcellsarationaleforcombinationtreatment
AT fourniejj idelalisibimprovescd37antibodybi836826cytotoxicityagainstchemoresistantrelapseinitiatingcllcellsarationaleforcombinationtreatment
AT quilletmarya idelalisibimprovescd37antibodybi836826cytotoxicityagainstchemoresistantrelapseinitiatingcllcellsarationaleforcombinationtreatment

Ejemplares similares